UK drug developer BTG reported positive interim data from a US Phase II safety study of its Varisolve (polidocanol), a foam-injection treatment for varicose veins, at the March annual meeting of the Society of Interventional Radiologists. The trial found no new magentic resonance imaging lesions, neurological or other visual field abnormalities or elevated cardiac markers being observed in the first 28 of the required 50 patients with bubbles detected in the middle cerebral artery following treatment with Varisolve. The study continues to progress well, the firm noted.
The structure of the overall Phase III program and the pivotal Phase III study designs have been agreed with the US Food and Drug Adminsitration. To validate aspects of the study protocols and to enable a Special Protocol Assessment to be sought later in 2008, BTG plans to conduct a Phase III pilot study and other key Phase III activities over the coming six months.
Significant progress has also been made with the product's design and manufacturing. A smaller, lower-cost, user-friendly single-canister presentation has now replaced the bulkier two-can product. Manufacturing has been contracted to a third party, and the new process and pilot plant have been fully validated, BTG added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze